The phase II HERMIONE trial was halted after the antibody-drug conjugate MM-302 combined with trastuzumab (Herceptin) failed to improve progression-free survival (PFS) versus chemotherapy plus trastuzumab in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1, Kadcyla).
Alopecia and hand-foot syndrome were observed in 10% and 4% of patients, respectively. One patient experienced a dose-limiting toxicity due to febrile neutropenia and a maximum tolerated dose was not reached. One patient experienced grade 1 cardiac failure, resulting in treatment discontinuation.
Patricia LoRusso P, Krop I, Miller K, et al. A Phase 1 study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer (mBC). Presented at: 2015 AACR Annual Meeting; April 18-22, 2015; Philadelphia, PA. Abstract 8855.
... to read the full story